GSK’s RSV vaccine Arexvy shown to protect older adults across three seasons
Tony Wood, GSK’s chief scientific officer, said: “We are excited by this new data which shows that a single dose of Arexvy could help protect millions of older adults at risk of RSV disease over three seasons to benefit public health. This is the only RSV vaccine with efficacy and safety data available through three full seasons.”